Physician profile
Norman Pflaster
NPI 1548234768
$40,424.43
in general payments reported to CMS, 2019-2025
59 companies · $864 in 2025
The $864 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,804 · 2020: $12K · 2021: $15K · 2022: $6,029 · 2023: $3,649 · 2024: $152 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,416 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,415.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16,673.98 | 2021-2025 | |
| Allergan, INC. | $12,333.66 | 2019-2022 | |
| Ucb, INC. | $1,189.81 | 2019-2025 | Fintepla, Briviact |
| Amgen INC. | $711.50 | 2019-2025 | Uplizna |
| Sk Life Science, INC. | $705.23 | 2020-2025 | |
| Biogen, INC. | $658.60 | 2019-2022 | |
| Horizon Therapeutics Plc | $593.34 | 2021-2023 | Uplizna |
| Lundbeck LLC | $568.75 | 2019-2023 | Vyepti |
| Acadia Pharmaceuticals INC | $511.55 | 2019-2023 | Nuplazid |
| Harmony Biosciences LLC | $501.22 | 2021-2023 | Wakix |
| Adamas Pharmaceuticals, INC. | $396.75 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $380.20 | 2019-2022 | |
| Emd Serono, INC. | $372.74 | 2019-2023 | Mavenclad |
| Greenwich Biosciences, INC. | $347.27 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $338.53 | 2019-2023 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Pflaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.